Recent Federal Circuit decisions have sown confusion among patent practitioners regarding core aspects of US patent law, including induced infringement, patent eligibility, written description, and enablement. Although the Supreme Court recently declined to provide needed clarity on patent eligibility in American Axle, it still has several opportunities in the coming months to address other critical issues for the LSPN community. In the meantime, the legislative and executive branches are embarking on their own efforts to enact legislation and regulations designed to clarify patent eligibility with respect to diagnostics, create a more predictable and powerful PTAB for petitioners and patent owners, and mandate closer collaboration between the USPTO and FDA. Topics to be covered in this session will include: